MOUNTAIN VIEW, Calif. — Genetic testing company 23andMe Inc. will comply with a Food and Drug Administration directive to stop providing access to health-related reports from its tests during a regulatory review.
The Mountain View, Calif., company said late Thursday that it will continue to provide ancestry-related information to customers and raw genetic data without interpretation. Those customers could receive additional, health-related information in the future, depending on whether the FDA grants marketing authorization.
Customers who bought kits since the FDA order came out late last month also will be eligible for refunds. Full story for BostonGlobe.com subscribers.